ABSTRACT
Osteoclasts, the multinucleated cells that resorb bone, develop from hematopoietic cells of monocyte/macrophage lineage. Osteoclast-like cells (OCLs) are formed by coculturing spleen cells with osteoblasts or bone marrow stromal cells in the presence of bone-resorbing factors. The cell-to-cell interaction between osteoblasts/stromal cells and osteoclast progenitors is essential for OCL formation. Recently, we purified and molecularly cloned osteoclastogenesis-inhibitory factor (OCIF), which was identical to osteoprotegerin (OPG). OPG/OCIF is a secreted member of the tumor necrosis factor receptor family and inhibits osteoclastogenesis by interrupting the cell-to-cell interaction. Here we report the expression cloning of a ligand for OPG/OCIF from a complementary DNA library of mouse stromal cells. The protein was found to be a member of the membrane-associated tumor necrosis factor ligand family and induced OCL formation from osteoclast progenitors. A genetically engineered soluble form containing the extracellular domain of the protein induced OCL formation from spleen cells in the absence of osteoblasts/stromal cells. OPG/OCIF abolished the OCL formation induced by the protein. Expression of its gene in osteoblasts/stromal cells was up-regulated by bone-resorbing factors. We conclude that the membrane-bound protein is osteoclast differentiation factor (ODF), a long-sought ligand mediating an essential signal to osteoclast progenitors for their differentiation into osteoclasts. ODF was found to be identical to TRANCE/RANKL, which enhances T-cell growth and dendritic-cell function. ODF seems to be an important regulator in not only osteoclastogenesis but also immune system.
Subject(s)
Carrier Proteins , Cell Communication/drug effects , DNA, Complementary/genetics , Glycoproteins/agonists , Membrane Glycoproteins/genetics , Membrane Glycoproteins/pharmacology , Osteoclasts/cytology , Receptors, Cytoplasmic and Nuclear , Stromal Cells/cytology , Animals , Bone Marrow Cells/cytology , Cell Differentiation/drug effects , Cell Line , Cloning, Molecular , DNA, Complementary/isolation & purification , Glycoproteins/pharmacology , Ligands , Mice , Molecular Sequence Data , Osteoprotegerin , RANK Ligand , Receptor Activator of Nuclear Factor-kappa B , Receptors, Tumor Necrosis FactorABSTRACT
Osteoclastogenesis inhibitory factor (OCIF) is present naturally as two molecular forms, a monomer and a homodimer. The two forms of recombinant human OCIF (rOCIF) produced by Chinese hamster ovary (CHO) cells were purified to homogeneity. Determination of the C-terminal amino-acid sequences of the two forms of rOCIF revealed that the monomeric rOCIF lacked several amino acids including Cys379, which is involved in the intermolecular disulfide bond, in its C-terminal region. The two forms of rOCIF were indistinguishable in stability, sialic acid content, and specific activity in inhibition of osteoclastogenesis. In contrast, the homodimeric rOCIF was stronger in heparin-binding ability than the monomeric rOCIF. The homodimeric rOCIF was significantly shorter in initial half-life and smaller in AUC value in rats than the monomeric rOCIF, but exerted more potent biological activity in reducing the calcium concentration in serum of rats than did the monomeric rOCIF.
Subject(s)
Glycoproteins/chemistry , Receptors, Cytoplasmic and Nuclear , Amino Acid Sequence , Animals , CHO Cells , Calcium/blood , Cricetinae , Dimerization , Disulfides/chemistry , Glycoproteins/pharmacokinetics , Heparin/metabolism , Humans , Molecular Sequence Data , N-Acetylneuraminic Acid/analysis , Osteoprotegerin , Protein Binding/physiology , Receptors, Tumor Necrosis Factor , Recombinant Proteins/chemistry , Sequence AnalysisABSTRACT
A cDNA encoding M2-type pyruvate kinase from mouse was cloned and its nucleotide sequence was determined. The cDNA encoded a protein containing 531 amino acids, the nucleotide and amino acid sequences of which were 93.2% and 98.1%, respectively, homologous to those of rat M2 pyruvate kinase. Expression of the pyruvate kinase in mouse embryonal carcinoma P19 cells altered according to differentiation stages; high at undifferentiated and low at differentiated stages.
